Clinical Biomarkers Market Report 2026

The clinical biomarkers market size has grown rapidly in recent years. It will grow from $33.75 billion in 2025 to $37.6 billion in 2026 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to growth in biomedical research activities, increasing clinical trial volumes, expansion of diagnostic testing capabilities, rising adoption of molecular diagnostics, improvements in analytical technologies.

The clinical biomarkers market size is expected to see rapid growth in the next few years. It will grow to $59.44 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to increasing demand for personalized therapies, rising investments in biomarker-driven drug development, expansion of translational research programs, growing use of real-world clinical data, increasing adoption of advanced sequencing technologies. Major trends in the forecast period include increasing adoption of precision medicine biomarkers, rising use of multi-omics biomarker platforms, growing integration of AI-based biomarker analytics, expansion of companion diagnostics development, enhanced focus on early disease detection.

The growing aging population is expected to drive the expansion of the clinical biomarkers market in the coming years. An aging population represents a demographic trend marked by a rising proportion of elderly individuals within societies over time. As the global population ages, the prevalence of age-related diseases increases, creating greater demand for biomarkers that support early diagnosis, monitoring, and effective disease management. For instance, in February 2025, according to the World Health Organization, a UK-based intergovernmental organization, the global population aged 60 years and above is projected to increase from 1.1 billion in 2023 to 1.4 billion by 2030. Therefore, the rising aging population is contributing to the growth of the clinical biomarkers market.

Major companies operating in the clinical biomarkers market are concentrating on the development of innovative solutions such as biomarker-based blood tests. A biomarker blood test is a diagnostic approach that measures specific biomolecules in the blood to provide insights into various physiological or disease-related conditions. For example, in July 2023, Quanterix Corporation, a US-based company specializing in ultra-sensitive digital immunoassay platforms, launched LucentAD, a biomarker blood test designed to support the assessment of patients showing cognitive symptoms associated with early signs of Alzheimer’s disease. LucentAD utilizes the well-studied Simoa p-Tau 181 assay, which has been extensively evaluated in large-scale longitudinal and cross-sectional studies.

In July 2024, Thermo Fisher Scientific Inc., a US-based global life sciences and laboratory equipment company, completed the acquisition of Olink Holding AB for an undisclosed amount. This acquisition is intended to strengthen Thermo Fisher’s leadership in the rapidly expanding proteomics market, enhance its precision research and diagnostic capabilities, and broaden its portfolio of high-throughput protein analysis solutions. Olink Holding AB is a Sweden-based biotechnology company that specializes in advanced proteomics technologies for high-resolution protein measurement in research and clinical settings.

Major companies operating in the clinical biomarkers market are Johnson and Johnson Services Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific, Agilent Technologies Inc., Epigenomics AG, Grifols S.A., Illumina Inc., BioMerieux SA., Charles River Laboratories International Inc., PerkinElmer Inc., Sartorius AG, Sysmex Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., Myriad Genetics Inc., Luminex Corporation, Veracyte Inc., Centogene N.V., NanoString Technologies Inc., Enzo Biochem Inc., Biocartis Group NV, Agendia Inc., Siemens Healthcare Private Limited.

North America was the largest region in the clinical biomakers market in 2025. The regions covered in the clinical biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the clinical biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the clinical biomarkers market by increasing costs of imported reagents, assay kits, sequencing instruments, diagnostic consumables, and analytical software tools. Research laboratories and diagnostic centers in North America and Europe are most affected due to dependence on imported high-precision instruments, while Asia-Pacific faces higher costs in biomarker kit production. These tariffs are increasing testing costs and slowing research timelines. However, they are also encouraging local reagent manufacturing, regional instrument assembly, and domestic innovation in biomarker discovery technologies.

The clinical biomarkers market research report is one of a series of new reports that provides clinical biomarkers market statistics, including clinical biomarkers industry global market size, regional shares, competitors with a clinical biomarkers market share, detailed clinical biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the clinical biomarkers industry. This clinical biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Clinical biomarkers are measurable biological characteristics that indicate normal or pathological processes within the body, such as chemical substances or physiological indicators. They support improved patient care and personalized medicine by providing important information on an individual’s health status, disease progression, and potential therapeutic targets.

The primary offerings in the clinical biomarkers market include products and services. A product refers to any item, whether tangible or intangible, that is offered to meet customer needs, and clinical biomarker products are used to support the diagnosis of diseases and medical conditions. Key technologies involved include next-generation sequencing, polymerase chain reaction, immunohistochemistry, enzyme-linked immunosorbent assay, and others. Clinical biomarker applications span multiple areas such as cancer biomarkers, cardiac biomarkers, neurological biomarkers, infectious disease biomarkers, immunological biomarkers, non-invasive prenatal testing, and others. These solutions are used across applications including clinical diagnostics and translational research, and by various end users such as contract research organizations, research and academic laboratories, biopharmaceutical and biotechnology companies, diagnostic centers, and others.

The clinical biomarkers market consists of revenues earned by entities by providing services such as biomarker assay development, biomarker testing, and biomarker data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The clinical biomarkers market also includes sales of immunoassay kits, point-of-care testing devices, and genetic testing panels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.